Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug
ReutersFeb 3, 2026 2:29 PM
Shares of drug developer Prelude Therapeutics PRLD.O rise 6.85% to $2.13 premarket
Company says U.S. FDA has cleared human testing of its experimental drug, PRT12396, for polycythemia vera and myelofibrosis — blood cancers where the body makes too many abnormal blood cells
PRLD says the early-stage study will assess safety and initial signs of benefit in patients with high-risk disease
PRT12396 is designed to target a genetic mutation common in both conditions - PRLD
Company expects to begin enrolling patients by Q2 2026 and says it has an exclusive option deal on the program with Incyte INCY.O
Shares more than doubled in 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
4 hours ago
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
4 hours ago
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first tTradingKey
6 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
